Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 112.36% | 122.89% | 177.68% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.67% | -19.08% | 20.87% | -- | -- |
| Operating Income | 21.67% | 19.08% | -20.87% | -- | -- |
| Income Before Tax | 35.60% | 29.05% | -10.08% | -- | -- |
| Income Tax Expenses | 100.56% | 100.56% | -159.08% | -- | -- |
| Earnings from Continuing Operations | 35.44% | 28.87% | -9.16% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.44% | 28.87% | -9.16% | -- | -- |
| EBIT | 21.67% | 19.08% | -20.87% | -- | -- |
| EBITDA | 21.77% | 19.14% | -20.84% | -- | -- |
| EPS Basic | 94.60% | 86.65% | 33.64% | -- | -- |
| Normalized Basic EPS | 94.61% | 86.68% | 33.19% | -- | -- |
| EPS Diluted | 94.60% | 86.65% | 33.64% | -- | -- |
| Normalized Diluted EPS | 94.61% | 86.68% | 33.19% | -- | -- |
| Average Basic Shares Outstanding | 916.68% | 984.60% | 285.78% | -- | -- |
| Average Diluted Shares Outstanding | 916.68% | 984.60% | 285.78% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |